Revolutionizing the Way We Treat Heart Failure
Heart failure kills more people globally than any other ailments, yet there is no ultimate treatment for the condition. Our goal is to develop and commercialize an effective and reasonably-priced therapy for heart failure using a specific fibroblast cells we call “VCF”, that we obtain from the patient’s own heart.
Our approach to heart failure therapy is quite different from other technologies in a sense that we do not want to replace what is “broken”, but rather we want to repair the damage by enhancing the cells’ own ability to heal.
Heart failure kills more people globally than any other ailments, yet there is no ultimate treatment for the condition. Our goal is to develop and commercialize an effective and reasonably-priced therapy for heart failure using a specific fibroblast cells we call “VCF”, that we obtain from the patient’s own heart.
Our approach to heart failure therapy is quite different from other technologies in a sense that we do not want to replace what is “broken”, but rather we want to repair the damage by enhancing the cells’ own ability to heal.
Location: Japan, Kawasaki
Employees: 11-50
Total raised: $30.8M
Investors 6
| Date | Name | Website |
| - | Sony Innov... | sonyinnova... |
| - | MAKOTO CAP... | mkto-capit... |
| 10.07.2026 | The Univer... | ut-ec.co.j... |
| - | Beyond Nex... | beyondnext... |
| - | Eight Road... | eightroads... |
| - | J-Startup | j-startup.... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 29.06.2022 | Series C | $14M | - |
| 04.01.2021 | Series B | $12.8M | - |
| 20.05.2020 | Series B | $4M | - |
Mentions in press and media 7
| Date | Title | Description |
| 05.07.2022 | Metcela Closes $14M Series C Financing | Metcela, a Kanagawa, Japan-based clinical-stage biotechnology company developing first-in-class autologous cell therapies targeting serious cardiovascular diseases, raised $14M in Series C funding. The round was led by CYBERDYNE Inc. and CE... |
| 29.06.2022 | Metcela Inc. Completes the Series C Financing of Total $14 Million | KANAGAWA, Japan (PRWEB) June 29, 2022 Metcela, a clinical-stage biotechnology company developing first-in-class autologous cell therapies targeting serious cardiovascular diseases, today announced the closing of a $14 million Series C round... |
| 04.01.2021 | Metcela Raises $12.7M in Series B Financing | Metcela, a Kanagawa, Japan-based clinical-stage biotech startup specializing in fibroblast-based cell therapy, raised $12.7M in Series B financing. The round was led by The University of Tokyo Edge Capital Partners (UTEC), with participatio... |
| 04.01.2021 | Metcela Secures $12.7 Million Series B Financing to Initiate Phase I Clinical Trial in Chronic Heart Failure for MTC001 Cell Therapy | KANAGAWA, Japan (PRWEB) January 04, 2021 Metcela is a clinical-stage Kanagawa-based biotech company bringing cell-based therapies to heart failure patients. Metcela’s lead asset, MTC001 is a cell therapy based on VCAM-1-positive Cardiac Fib... |
| 04.01.2021 | Metcela Inc. announced that it has received ¥1.32 billion in funding from a group of investors | On January 4, 2021, Metcela Inc. closed the transaction. The company amended the terms of the transaction, and received ¥890,000,000 in its second tranche closing, bringing the total gross proceeds raised in the transaction to ¥1,320,000,00... |
| 20.05.2020 | Metcela Raises $4M in Series B Funding | Metcela Inc., a Tsuruoka-shi, Yamagata, Japan-based biotech startup specializing in fibroblast-based cell therapy, closed its 430m yen ($4m) Series B funding round. Backers included Japan Lifeline Co., Ltd. (JLL), Sony Innovation Fund and T... |
| 04.10.2019 | Tokyo-based Startup Secures $42.9M Series B To Diagnose Gastric Cancer Earlier With AI | 16 Shares Email Facebook Twitter LinkedIn Tokyo-based AI Medical Service Inc., which is developing endoscopic software powered by artificial intelligence, announced today that it has raised $42.9 million in a Series B round. Subscribe to th... |